AVIR Aviragen Therapeutics, Inc.

0.70
-0.01  -0.45%
Previous Close 0.70
Open 0.70
Price To book 0.97
Market Cap 26.97M
Shares 38,649,000
Volume 81,288
Short Ratio 1.37
Av. Daily Volume 126,352

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a data released February 1, 2017 - primary endpoint not met.
BTA585
Respiratory syncytial virus (RSV)
Phase 2 ongoing.
BTA074 5% topical gel
Condyloma
Phase 2b top-line data released February 13, 2017 - primary endpoint not met.
Vapendavir - SPIRITUS trial
Human rhinovirus (HRV)
Phase 2 initiated Jun 2013. Topline data did not meet the primary endpoint - July 2014
Laninamivir Octanoate - IGLOO
Adults with symptomatic influenza A or B infection

Latest News

  1. Aviragen Therapeutics downgraded by H.C. Wainwright
  2. Aviragen Tanks on Second Antiviral Drug Failure
  3. Aviragen Therapeutics Announces Top-Line Results from Phase 2b SPIRITUS Trial of Vapendavir
  4. AVIRAGEN THERAPEUTICS, INC. Financials
  5. AVIRAGEN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
  6. AVIRAGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
  7. Aviragen Therapeutics Reports Second Quarter Fiscal Year 2017 Financial Results
  8. Aviragen Hits 52-Week Low After Drug Fails Trial
  9. AVIRAGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  10. Q2 2017 Aviragen Therapeutics Inc Earnings Release - After Market Close
  11. Aviragen Therapeutics Announces Top-Line Results from Phase 2a RSV Challenge Study of BTA585
  12. Aviragen Therapeutics to Host Conference Call to Report Second Quarter Fiscal Year 2017 Financial Results on February 2, 2017
  13. Aviragen Therapeutics Inc (AVIR) Could Start To Move Near Term
  14. AVIRAGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  15. Immunomedics Announces Reconstituted Board of Directors and Leadership Succession Plan
  16. Edited Transcript of AVIR earnings conference call or presentation 3-Nov-16 8:30pm GMT
  17. Aviragen Therapeutics Reports First Quarter Fiscal Year 2017 Financial Results
  18. Aviragen Therapeutics to Host Conference Call to Report First Quarter Fiscal Year 2017 Financial Results on November 3, 2016
  19. AVIRAGEN THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
  20. AVIRAGEN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report